Basics Axon Holdings S.A. Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia. IPO Date: June 11, 2015 Sector: Industrials Industry: Aerospace and Defense Market Cap: $59.06B Activated in VL: True Average Daily Range Avg Daily Range: $2.44 | 2.44% Avg Daily Range (30 D): $9.71 | 1.43% Avg Daily Range (90 D): $13.19 | 2.22% Institutional Daily Volume Avg Daily Volume: .62M Avg Daily Volume (30 D): .44M Avg Daily Volume (90 D): .59M Trade Size Avg Trade Size (Sh.): 79 Avg Trade Size (Sh.) (30 D): 19 Avg Trade Size (Sh.) (90 D): 23 Institutional Trades Total Inst.Trades: 3,119 Avg Inst. Trade: $13.67M Avg Inst. Trade (30 D): $30.22M Avg Inst. Trade (90 D): $29.05M Avg Inst. Trade Volume: .06M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $23.3M Avg Closing Trade (30 D): $60.76M Avg Closing Trade (90 D): $58.69M Avg Closing Volume: 84.84K     News Jun 8, 2025 @ 7:32 AM 2 High-Growth Stocks to Buy and Hold for Great Lon... Source: John Ballard Jun 2, 2025 @ 3:39 PM AXON: Competition Intensifies as Motorola Makes $4... Source: Marketbeat.Com May 15, 2025 @ 1:12 PM Is Axon Stock Too Expensive—or Just Getting... Source: Marketbeat.Com May 8, 2025 @ 3:00 PM Why Axon Enterprise Stock Is Charging Higher Today... Source: Lou Whiteman May 8, 2025 @ 2:20 PM Axon Hits the Mark to Start 2025 Source: Dan Caplinger Financials   TTM Q3 2024 Q2 2024 Basic EPS $1.14 $.89 $.55 Diluted EPS $1.08 $.86 $.53 Revenue $ 603.63M $ 544.27M $ 503.24M Gross Profit $ 365.74M $ 330.75M $ 306.16M Net Income / Loss $ 87.98M $ 67.03M $ 41.47M Operating Income / Loss $ -8.79M $ 24.08M $ 33.76M Cost of Revenue $ 237.89M $ 213.53M $ 197.08M Net Cash Flow $ 638M $ 128.84M $ 162.61M PE Ratio 0.00     Splits Sep 28, 2007:   1:600 Nov 30, 2004:   2:1 Apr 30, 2004:   2:1 Feb 11, 2004:   3:1